Efficacy and safety of ziltivekimab in patients with chronic kidney disease susceptible to inflammatory diseases: a systematic review and meta-analysis of randomized controlled trials

• Main Authors: Amr Elrosasy (Author), Dalal Sabbagh (Author), Mohammad Assaf (Author), Husam Tarakhan (Author), Ahmad Afyouni (Author), Marwa O. Elgendy (Author), Lamiaa N. Abdelaty (Author), Refaat H. Omar (Author), Ahmed Hamdy Zabady (Author)
• Format: Book
• Published: SpringerOpen, 2024-11-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Background Patients with chronic kidney disease (CKD) are at risk of developing conditions such as atherosclerosis and inflammation-induced anemia (AI) due to persistent inflammation. Ziltivekimab, an antibody targeting interleukin-6, is being studied for its potential to reduce inflammator...